Samsung Biologics to Acquire Swiss Peptide CDMO for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance

Samsung Biologics (207940.KS) announced on the 20th that it will acquire PolyPeptide Group, a global peptide contract development and manufacturing organization (CDMO) based in Switzerland, for approximately 2.7 trillion won (1.46 billion Swiss francs). This is the largest merger and acquisition (M&A) deal in the history of South Korea’s pharmaceutical and biotech industry.

Samsung Biologics plans to secure a 100% stake in PolyPeptide Group through the acquisition of majority shareholder stakes and a public tender offer. The largest…